EverSource Wealth Advisors’s Sage Therapeutics SAGE Stock Holding History

EverSource Wealth Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,782	Closed	-$25.4K	–	4452
2025 Q2	$25.4K	Buy	2,782 +1,404	+102%	+$10.3K	﹤0.01%	2111
2025 Q1	$11K	Buy	1,378 +1,377	+137,700%	+$10.1K	﹤0.01%	2064
2024 Q4	$5	Buy	+1	New	+$6	﹤0.01%	3742
2023 Q4	–	Sell	-119	Closed	-$2.45K	–	2728
2023 Q3	$2.45K	Buy	119 +95	+396%	+$2.74K	﹤0.01%	1953
2023 Q2	$1.13K	Sell	24 -17	-41%	-$846	﹤0.01%	2177
2023 Q1	$1.72K	Buy	+41	New	+$1.76K	﹤0.01%	1980

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

EverSource Wealth Advisors's SAGE Position: Q3 2025 in Review

EverSource Wealth Advisors sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 2,782 shares — an estimated $25.4K sold.

EverSource Wealth Advisors first reported a position in SAGE in Q1 2023 and held it in 6 quarters. The position peaked at $25.4K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

EverSource Wealth Advisors reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
EverSource Wealth Advisors sold 2,782 Sage Therapeutics shares in Q3 2025, an estimated $25.4K.
EverSource Wealth Advisors first reported a position in Sage Therapeutics in Q1 2023 and held it in 6 quarters.
EverSource Wealth Advisors's Sage Therapeutics position peaked at $25.4K in Q2 2025.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on EverSource Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.